Ring Therapeutics is a biotechnology research company based in Cambridge, Massachusetts. Founded in 2017 by Flagship Pioneering, Ring is powering a new era of gene therapy by harnessing the unique biology of commensal anelloviruses. Their research aims to develop anellovirus-based therapies with tissue and cellular tropism, payload versatility, potency, and redosability.

Noubar Afeyan

Avak Kahvejian

Erica Weinstein

Ring Therapeutics

Flagship Pioneering

Invus

Partners Investment

T. Rowe Price

UPMC Enterprises

Altitude Life Science Ventures

CJ Investment

Alexandria Venture Investments

Kyowa Kirin

#ICYMI we presented our first NHP data on our #Anellovectors and #AnelloBricks platform at #ESGCT2023. We’re dedicated to revolutionizing the gene therapy and nucleic acid medicine space. Catch up on the data presented here: https://brnw.ch/21wEiKw

Last week, our team took a break from the lab bench and headed out on a city-wide scavenger hunt for a chance to explore our new neighborhood in East Cambridge. Check out these selfies and sites from the competition & congrats to our winners Ashley Tang , Daniel Elliott MBA, SHRM-SCP, Gowtham Akash Jayakumar, Jake Matte, Kavya Atluri, Patricio Jeraldo, and Laurindo Fonseca for taking home the prize during this exciting team bonding activity!

We’ve landed in Brussels for #ESGCT2023! Come stop by and check out our posters showcasing the first NHP transduction data for our #Anellovectors and #AnelloBricks platform. If you can't make it, check out poster details here: https://brnw.ch/21wDRy3

This week, we are presenting new data at the 30th Annual European Society of Gene and Cell Therapy (ESGCT) Conference! Come check out our posters where Geoffrey Parsons will highlight the first NHP transduction data for #Anellovectors and our unique manufacturing approach with #AnelloBricks. Read more about our data here:  https://lnkd.in/eTzKS8td #ESGCT2023

Our #CEO Dr. Tuyen Ong was recently featured in a Genetic Engineering & Biotechnology News article discussing how anelloviruses can address current challenges in genetic medicine and the potential of AnelloVectors from our #Anellogy platform. Read more: https://brnw.ch/21wDorc

At Ring, we're translating the unique biology of commensal anelloviruses into AnelloVectors with our #Anellogy platform.  Learn more about how we're transforming these commensal viruses into life-saving therapies: https://brnw.ch/21wDcIe

We are incredibly proud to be part of Flagship Pioneering as we take bold leaps to tackle challenges in genetic medicine. At Ring, we’re committed to pushing the boundaries of what is possible with our #Anellogy platform. #FlagshipFounded

Today we announced two late-breaking presentations at the 30th Annual European Society of Gene and Cell Therapy (ESGCT) conference in Brussels! Come check out new data from our #Anellogy platform and learn about our unique approach to #genetherapy manufacturing. Read more about our presentation details here: https://brnw.ch/21wCWC7 #ESGCT2023

This summer, we transitioned to a new space to support the growth of our team! This space was meticulously designed to inspire brilliance & collaboration so we can continue pushing boundaries in genetic medicine with our #Anellogy platform. Join us: https://brnw.ch/21wCQrd

#TBT Our CEO Dr. Tuyen Ong chatted with Jonathan Grinstein from Genetic Engineering & Biotechnology News about addressing safety in gene editing and the importance of derisking novel approaches. Click here to read more:  https://fal.cn/3AqY4

Metric
Company Name	Ring Therapeutics
Symbol
MSH ID	COM:RINGTX
Market	PRIVATE
Sector	Healthcare
Industry	Biotechnology Research
Country	US
Stage	Series C
Employee Count	120
Website	ringtx.com
LinkedIn	ring-therapeutics
Founders

Metric
Market Cap	315.90M
Enterprise Value
Monthly Web Traffic	2.25K
Web Traffic Growth	2.01
Valuation
Raised Capital	86.50M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:RINGTX

Ring Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue